TPA-assisted vitrectomy for proliferative diabetic retinopathy: Results of a double-masked, multicenter trial

Retina

Volumn 19, Issue 5, 1999, Pages 378-382

  Le Mer, Yannick ^a   Korobelnik, JEAN FRANÇOIS ^b   Morel, Christophe ^c   Ullern, Martine ^c   Berrod, Jean Paul ^d  

^a Centre Hospitalier Intercommunal Andre Gregoire   (France)

^b FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^c Centre Hospitalier National d Ophtalmologie des 15 20   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Complications; Proliferative diabetic retinopathy; Tissue plasminogen activator; Vitrectomy

Indexed keywords

ALTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY; VITRECTOMY;

EID: 0033506960     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-199909000-00002     Document Type: Article

References (26)

1. Han DP, Abrams GW, Aaberg TM. Surgical excision of the attached posterior hyaloid. Arch Ophthalmol 1988;106:998-1000.
2. Mein CE, Flynn HW Jr. Recognition and removal of the posterior cortical vitreous during vitreoretinal surgery for impending macular hole. Am J Ophthalmol 1991;111:611-613.
3. Vander JF, Kleiner R. A method for induction of posterior vitreous detachment during vitrectomy. Retina 1992;12:172-173.
4. Banker AS, Freeman WR, Kim JW, et al. Vision-threatening complications of surgery for full-thickness macular holes. Vitrectomy for Macular Hole Study Group. Ophthalmology 1997; 104:1442-1452.
5. Bopp S, Lucke K, Hille U. Peripheral visual field loss after vitreous surgery for macular holes. Graefes Arch Clin Exp Ophthalmol 1997;235:362-371.
6. Pendergast SD, McCuen BW II. Visual field loss after macular hole surgery. Ophthalmology 1996;103:1069-1077.
7. Paques M, Massin P, Santiago PY, et al. Visual field loss after vitrectomy for full-thickness macular holes. Am J Ophthalmol 1997;124:88-94.
8. Casaroli RP, Vilaro S. The role of fibronectin, laminin, vitreonectin and their receptors on cellular adhesion in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1994;35: 2791-2803.
9. Yamada KM. Fibronectin and other cell interactive glycoproteins. In: Hay ED, ed. Cell Biology of Extracellular Matrix. New York: Plenum Press, 1991:111-146.
10. Peczon BD, Wolfe JK, Gipson IK, et al. Characterization of membranes removed during open-sky vitrectomy. Invest Ophthalmol Vis Sci 1983;24:1382-1389.
11. Gottlieb JL, Antoszyk AN, Hatchell DL, Saloupis P. The safety of intravitreal hyaluronidase. A clinical and histologic study. Invest Ophthalmol Vis Sci 1990;31:2345-2352.
12. Kang SW, Hyung SM, Choi MY, Lee I. Induction of vitreolysis and vitreous detachment with hyaluronidase and perfluoropropane gas. Korean J Ophthalmol 1995;9:69-78.
13. Yao XY, Hageman GS, Marmor MF. Retinal adhesiveness is weakened by enzymatic modification of the interphotoreceptor matrix in vivo. Invest Ophthalmol Vis Sci 1990;31:2051-2058.
14. Yao XY, Hageman GS, Mannor MF. Recovery of retinal adhesion after enzymatic perturbation of the interphotoreceptor matrix. Invest Ophthalmol Vis Sci 1992;33:498-503.
15. Verstraeten TC, Chapman C, Hartzer M, et al. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol 1993;111:849-854.
16. Collen D. Biological properties of plasminogen activators. In: Sobel BE, Collen D, Grosbard EB. Tissue Plasminogen Activators in Thrombolytic Therapy, 1st ed. New York: Marcel Dekker Inc., 1987;1:3-24.
17. Jaffe GJ, Green GDJ, Abrams GW. Stability of recombinant tissue plasminogen activator. Am J Ophthalmol 1989;108:90-91.
18. Jaffe GJ, Abrams GW, Williams GA. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology 1990;97:184-189.
19. Lewis H, Resnick SC, Flannery JG, Straatsma BR. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol 1991;111:197-204.
20. Coll GE, Sparrow JR, Marinovic A, Chang S. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995;15:319-326.
21. Johnson MW, Olsen KR, Hernandez E. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990;108:259-263.
22. Johnson RN, Olsen KR, Hernandez E. Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage. Arch Ophthalmol 1989;107:891-894.
23. Irvine WD, Johnson MW, Hernandez E, Olsen KR. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol 1991;109:718-722.
24. Hesse L, Chofflet J, Kroll P. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy. Ger J Ophthalmol 1995;4:323-327.
25. Dunn FW, Deguchi K, Soria J, et al. Importance of the interaction between plasminogen and fibrin for plasminogen activation by tissue-type plasminogen activator. Thromb Res 1984;36:345-351.
26. Jaffe GJ, Green GD, McKay BS, et al. Intravitreal clearance of tissue plasminogen activator in the rabbit. Arch Ophthalmol 1988;106:969-972.